Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: Results of a prospective study

Liver International

Volumn 26, Issue 7, 2006, Pages 834-839

  Schepke, Michael ^a   Appenrodt, Beate ^a   Heller, Jörg ^a   Zielinski, Julia ^a   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cirrhosis; Hepatorenal syndrome; MELD; Prognosis; Renal dysfunction

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CREATININE; MIDODRINE; OCTREOTIDE; TERLIPRESSIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FEMALE; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PARENCHYMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME;

AGED; CREATININE; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 33746703153     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01302.x     Document Type: Article

References (15)

1. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
2. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993; 105: 229-36.
3. Arroyo V, Gines P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
4. Allesandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to transplantation. Hepatology 2005; 41: 1282-9.
5. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38 (Suppl. 1): S69-89.
6. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
7. Kamath P S, Wiesner R, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
8. Wiesner R, Edwards E, United Network for Organ Sharing Liver Disease Severity Score Committee, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
9. Schepke M, Roth F, Fimmers R, et al. Comparison of MELD, Child-Pugh and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting (TIPS). Am J Gastroenterol 2003; 98: 1167-74.
10. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 27: 233-43.
11. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 35: 1646-54.
12. Schepke M, Roth F, Koch L, et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting (TIPS) for the prevention of variceal rebleeding. Digestion 2003; 76: 146-53.
13. Gines P, Martin P Y, Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int 1997; 52 (Suppl. 61): 77-82.
14. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46-52.
15. Schepke M, Kleber G, German Study Group for the Primary Prophylaxis of Variceal Bleeding, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40 (1): 65-72.